Is XRAY or CERS more profitable?

Cerus has a net margin of -4.41% compared to DENTSPLY SIRONA's net margin of -17.06%. DENTSPLY SIRONA's return on equity of 18.83% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets DENTSPLY SIRONA -17.06% 18.83% 5.13% Cerus -4.41% -15.18% -4.38%

Does the media favor XRAY or CERS?

In the previous week, Cerus had 4 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 7 mentions for Cerus and 3 mentions for DENTSPLY SIRONA. Cerus' average media sentiment score of 0.81 beat DENTSPLY SIRONA's score of 0.61 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DENTSPLY SIRONA 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cerus 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, CERS or NEOG?

Cerus has higher earnings, but lower revenue than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.53 -$15.63M -$0.05 N/A Neogen $894.66M 2.21 -$1.09B -$2.80 N/A

Is CERS or NEOG more profitable?

Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% Neogen -69.93% 2.35% 1.46%

Does the media prefer CERS or NEOG?

In the previous week, Cerus had 3 more articles in the media than Neogen. MarketBeat recorded 7 mentions for Cerus and 4 mentions for Neogen. Cerus' average media sentiment score of 0.81 beat Neogen's score of 0.12 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neogen 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is STAA or CERS more profitable?

Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets STAAR Surgical -7.24% 3.31% 2.55% Cerus -4.41% -15.18% -4.38%

Does the media refer more to STAA or CERS?

In the previous week, Cerus had 5 more articles in the media than STAAR Surgical. MarketBeat recorded 7 mentions for Cerus and 2 mentions for STAAR Surgical. Cerus' average media sentiment score of 0.81 beat STAAR Surgical's score of 0.34 indicating that Cerus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cerus 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CERS or QDEL more profitable?

Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% QuidelOrtho -45.57% 4.25% 1.56%

Does the media refer more to CERS or QDEL?

In the previous week, Cerus had 4 more articles in the media than QuidelOrtho. MarketBeat recorded 7 mentions for Cerus and 3 mentions for QuidelOrtho. Cerus' average media sentiment score of 0.81 beat QuidelOrtho's score of 0.20 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CERS or OSUR more profitable?

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cerus -4.41% -15.18% -4.38% OraSure Technologies -66.42% -18.57% -15.71%

Does the media refer more to CERS or OSUR?

In the previous week, Cerus had 6 more articles in the media than OraSure Technologies. MarketBeat recorded 7 mentions for Cerus and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.91 beat Cerus' score of 0.81 indicating that OraSure Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OraSure Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cerus (CERS) Competitors

$2.60 -0.11 (-4.06%)

Closing price 04:00 PM Eastern

Extended Trading

$2.51 -0.09 (-3.54%)

As of 07:58 PM Eastern

Compare

CERS vs. XRAY, NEOG, STAA, QDEL, and OSUR

Should you buy Cerus stock or one of its competitors? MarketBeat compares Cerus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cerus include DENTSPLY SIRONA (XRAY), Neogen (NEOG), STAAR Surgical (STAA), QuidelOrtho (QDEL), and OraSure Technologies (OSUR). These companies are all part of the "health care supplies" industry.

How does Cerus compare to DENTSPLY SIRONA?

DENTSPLY SIRONA (NASDAQ:XRAY) and Cerus (NASDAQ:CERS) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Cerus has lower revenue, but higher earnings than DENTSPLY SIRONA. Cerus is trading at a lower price-to-earnings ratio than DENTSPLY SIRONA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DENTSPLY SIRONA	$3.68B	0.56	-$598M	-$3.15	N/A
Cerus	$206.13M	2.53	-$15.63M	-$0.05	N/A

Cerus has a net margin of -4.41% compared to DENTSPLY SIRONA's net margin of -17.06%. DENTSPLY SIRONA's return on equity of 18.83% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DENTSPLY SIRONA	-17.06%	18.83%	5.13%
Cerus	-4.41%	-15.18%	-4.38%

DENTSPLY SIRONA currently has a consensus target price of $13.55, suggesting a potential upside of 32.02%. Cerus has a consensus target price of $4.00, suggesting a potential upside of 53.85%. Given Cerus' stronger consensus rating and higher possible upside, analysts clearly believe Cerus is more favorable than DENTSPLY SIRONA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

DENTSPLY SIRONA has a beta of 0.89, meaning that its stock price is 11% less volatile than the broader market. Comparatively, Cerus has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

95.7% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 3.4% of Cerus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Cerus had 4 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 7 mentions for Cerus and 3 mentions for DENTSPLY SIRONA. Cerus' average media sentiment score of 0.81 beat DENTSPLY SIRONA's score of 0.61 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DENTSPLY SIRONA	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cerus	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cerus beats DENTSPLY SIRONA on 10 of the 16 factors compared between the two stocks.

How does Cerus compare to Neogen?

Cerus (NASDAQ:CERS) and Neogen (NASDAQ:NEOG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

In the previous week, Cerus had 3 more articles in the media than Neogen. MarketBeat recorded 7 mentions for Cerus and 4 mentions for Neogen. Cerus' average media sentiment score of 0.81 beat Neogen's score of 0.12 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus has higher earnings, but lower revenue than Neogen. Cerus is trading at a lower price-to-earnings ratio than Neogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.53	-$15.63M	-$0.05	N/A
Neogen	$894.66M	2.21	-$1.09B	-$2.80	N/A

78.4% of Cerus shares are held by institutional investors. Comparatively, 96.7% of Neogen shares are held by institutional investors. 3.4% of Cerus shares are held by insiders. Comparatively, 0.6% of Neogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cerus has a net margin of -4.41% compared to Neogen's net margin of -69.93%. Neogen's return on equity of 2.35% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
Neogen	-69.93%	2.35%	1.46%

Cerus has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Neogen has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market.

Cerus presently has a consensus price target of $4.00, indicating a potential upside of 53.85%. Neogen has a consensus price target of $10.67, indicating a potential upside of 17.60%. Given Cerus' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cerus is more favorable than Neogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Cerus beats Neogen on 9 of the 15 factors compared between the two stocks.

How does Cerus compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and Cerus (NASDAQ:CERS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Cerus had 5 more articles in the media than STAAR Surgical. MarketBeat recorded 7 mentions for Cerus and 2 mentions for STAAR Surgical. Cerus' average media sentiment score of 0.81 beat STAAR Surgical's score of 0.34 indicating that Cerus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cerus	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 78.4% of Cerus shares are owned by institutional investors. 39.9% of STAAR Surgical shares are owned by insiders. Comparatively, 3.4% of Cerus shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

STAAR Surgical has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Cerus has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

STAAR Surgical presently has a consensus target price of $27.81, indicating a potential downside of 7.17%. Cerus has a consensus target price of $4.00, indicating a potential upside of 53.85%. Given Cerus' stronger consensus rating and higher probable upside, analysts plainly believe Cerus is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cerus has a net margin of -4.41% compared to STAAR Surgical's net margin of -7.24%. STAAR Surgical's return on equity of 3.31% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	-7.24%	3.31%	2.55%
Cerus	-4.41%	-15.18%	-4.38%

Cerus has lower revenue, but higher earnings than STAAR Surgical. STAAR Surgical is trading at a lower price-to-earnings ratio than Cerus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$239.44M	6.23	-$80.45M	-$0.43	N/A
Cerus	$206.13M	2.53	-$15.63M	-$0.05	N/A

Summary

Cerus beats STAAR Surgical on 9 of the 16 factors compared between the two stocks.

How does Cerus compare to QuidelOrtho?

Cerus (NASDAQ:CERS) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Cerus currently has a consensus target price of $4.00, suggesting a potential upside of 53.85%. QuidelOrtho has a consensus target price of $14.88, suggesting a potential upside of 2.80%. Given Cerus' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cerus is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Cerus had 4 more articles in the media than QuidelOrtho. MarketBeat recorded 7 mentions for Cerus and 3 mentions for QuidelOrtho. Cerus' average media sentiment score of 0.81 beat QuidelOrtho's score of 0.20 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cerus has higher earnings, but lower revenue than QuidelOrtho. Cerus is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.53	-$15.63M	-$0.05	N/A
QuidelOrtho	$2.73B	0.36	-$1.13B	-$17.82	N/A

Cerus has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Cerus has a net margin of -4.41% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat Cerus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
QuidelOrtho	-45.57%	4.25%	1.56%

78.4% of Cerus shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 3.4% of Cerus shares are held by insiders. Comparatively, 1.1% of QuidelOrtho shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Cerus beats QuidelOrtho on 11 of the 16 factors compared between the two stocks.

How does Cerus compare to OraSure Technologies?

Cerus (NASDAQ:CERS) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.53	-$15.63M	-$0.05	N/A
OraSure Technologies	$115.02M	2.48	-$68.73M	-$1.04	N/A

Cerus presently has a consensus price target of $4.00, suggesting a potential upside of 53.85%. OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 27.71%. Given Cerus' stronger consensus rating and higher probable upside, research analysts clearly believe Cerus is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cerus has a net margin of -4.41% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -15.18% beat OraSure Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-4.41%	-15.18%	-4.38%
OraSure Technologies	-66.42%	-18.57%	-15.71%

78.4% of Cerus shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 3.4% of Cerus shares are held by company insiders. Comparatively, 3.9% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Cerus has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

In the previous week, Cerus had 6 more articles in the media than OraSure Technologies. MarketBeat recorded 7 mentions for Cerus and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 0.91 beat Cerus' score of 0.81 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OraSure Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cerus beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

Get Cerus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CERS vs. The Competition

Export

Metric	Cerus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$543M	$8.48B	$6.49B	$11.99B
Dividend Yield	N/A	2.52%	2.67%	5.57%
P/E Ratio	-52.00	13.05	20.24	21.95
Price / Sales	2.53	7.13	507.57	108.00
Price / Cash	N/A	17.45	26.99	37.25
Price / Book	7.65	3.55	10.28	6.78
Net Income	-$15.63M	$225.32M	$3.57B	$337.51M
7 Day Performance	-8.45%	-1.06%	-1.43%	-2.72%
1 Month Performance	-0.38%	2.21%	3.27%	1.87%
1 Year Performance	72.19%	-3.10%	23.37%	26.61%

Cerus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CERS Cerus	3.0414 of 5 stars	$2.60 -4.1%	$4.00 +53.8%	+79.5%	$543M	$206.13M	N/A	290	News Coverage
XRAY DENTSPLY SIRONA	4.6123 of 5 stars	$9.91 -5.4%	$13.82 +39.5%	-37.3%	$2.10B	$3.68B	N/A	14,000
NEOG Neogen	1.707 of 5 stars	$8.78 -2.2%	$10.67 +21.6%	+70.8%	$1.94B	$870.56M	N/A	2,110
STAA STAAR Surgical	2.853 of 5 stars	$28.96 -3.1%	$27.81 -4.0%	+67.8%	$1.47B	$290.38M	N/A	1,211
QDEL QuidelOrtho	1.9311 of 5 stars	$12.81 -1.6%	$14.88 +16.1%	-51.5%	$887.85M	$2.73B	N/A	6,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CERS) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cerus (CERS) Competitors

CERS vs. XRAY, NEOG, STAA, QDEL, and OSUR

How does Cerus compare to DENTSPLY SIRONA?

Summary

How does Cerus compare to Neogen?

Summary

How does Cerus compare to STAAR Surgical?

Summary

How does Cerus compare to QuidelOrtho?

Summary

How does Cerus compare to OraSure Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cerus (CERS) Competitors

CERS vs. XRAY, NEOG, STAA, QDEL, and OSUR

How does Cerus compare to DENTSPLY SIRONA?

Which has stronger earnings and valuation, XRAY or CERS?

Is XRAY or CERS more profitable?

Do analysts recommend XRAY or CERS?

Which has more risk & volatility, XRAY or CERS?

Do institutionals and insiders have more ownership in XRAY or CERS?

Does the media favor XRAY or CERS?

Summary

How does Cerus compare to Neogen?

Does the media prefer CERS or NEOG?

Which has stronger earnings and valuation, CERS or NEOG?

Do institutionals & insiders believe in CERS or NEOG?

Is CERS or NEOG more profitable?

Which has more volatility & risk, CERS or NEOG?

Do analysts recommend CERS or NEOG?

Summary

How does Cerus compare to STAAR Surgical?

Does the media refer more to STAA or CERS?

Do institutionals and insiders believe in STAA or CERS?

Which has more volatility and risk, STAA or CERS?

Do analysts prefer STAA or CERS?

Is STAA or CERS more profitable?

Which has preferable valuation and earnings, STAA or CERS?

Summary

How does Cerus compare to QuidelOrtho?

Do analysts prefer CERS or QDEL?

Does the media refer more to CERS or QDEL?

Which has better valuation and earnings, CERS or QDEL?

Which has more volatility & risk, CERS or QDEL?

Is CERS or QDEL more profitable?

Do institutionals & insiders have more ownership in CERS or QDEL?

Summary

How does Cerus compare to OraSure Technologies?

Which has higher earnings & valuation, CERS or OSUR?

Do analysts prefer CERS or OSUR?

Is CERS or OSUR more profitable?

Do institutionals and insiders have more ownership in CERS or OSUR?

Which has more volatility and risk, CERS or OSUR?

Does the media refer more to CERS or OSUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CERS vs. The Competition

Cerus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools